Dapagliflozin in T1D: The DEPICT studies examined the efficacy and safety of add-on therapy with the SGLT2-i dapagliflozin in persons with poorly controlled T1D over 52 weeks (DEPICT-1 study; 833 participants) and 24 weeks (DEPICT-2; 1465 participants) of treatment. Here, SLC5A2 is linked to type 1 diabetes mellitus.